Skip to content

Insulin Isophane Human/Insulin Regular Human

    Brands

    DEA Class; OTC

    Common Brand Names; Humulin 70/30, Novolin 70/30

    • Antidiabetics, Insulins

    A combination of regular insulin and intermediate-acting insulin (NPH insulin); fixed-ratio mixtures
    Used for type 1 and type 2 diabetes mellitus
    For type 2 diabetes, most commonly given twice daily

    Indicated for the treatment of type 1 diabetes mellitus.

    For the treatment of type 2 diabetes mellitus.

    Hypoglycemia

    Documented hypersensitivity reactions to product or excipients

    Hypoglycemia

    Insulin resistance

    Lipodystrophy

    Lipohypertrophy

    Local allergic reaction

    Hypokalemia

    Localized cutaneous amyloidosis

    Never share pen between patients even if needle is changed

    Intermediate-acting insulin, do not use for circumstances that require rapid-acting insulin

    Caution with decreased insulin requirements (eg, diarrhea, nausea/vomiting, malabsorption, hypothyroidism, renal impairment, hepatic impairment)

    Caution with increased insulin requirements (eg, fever, hyperthyroidism, trauma, infection, surgery)

    Thiazolidinediones are peroxisome proliferator-activated receptor (PPAR)-gamma agonists and can cause dose-related fluid retention, particularly when used in combination with insulin; fluid retention may lead to or exacerbate heart failure, monitor for signs and symptoms of heart failure and treat accordingly and consider discontinuing thiazolidinediones

    Hypoglycemia may be life-threatening; increase frequency of blood glucose monitoring with changes to: insulin dosage, co-administered glucose lowering medications, meal pattern, physical activity; in patients with renal or hepatic impairment; and in patients with hypoglycemia unawareness

    Severe, life-threatening, generalized allergy, hypersensitivity, including anaphylaxis, can occur; discontinue therapy, monitor, and treat if indicated

    Available data from published studies over decades have not established association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal Outcomes

    Available data from published literature suggests that exogenous human insulin products, are transferred into human milk

    Specific maximum dosage information is not available. Individualize dosage based on careful monitoring of blood glucose and other clinical parameters in all patient populations.

    NPH, human insulin isophane rDNA origin/regular, human insulin rDNA origin

    Insulin isophane human/insulin regular human

    injectable suspension

    • (70 units/30 units)/mL